Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Authors
Keywords
-
Journal
Blood Advances
Volume 4, Issue 10, Pages 2192-2201
Publisher
American Society of Hematology
Online
2020-05-21
DOI
10.1182/bloodadvances.2020001779
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
- (2019) Rory M. Shallis et al. BLOOD REVIEWS
- Comparisons of commonly used frontline regimens on survival outcomes in patients age 70 years and older with acute myeloid leukemia
- (2019) Chetasi Talati et al. HAEMATOLOGICA
- RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
- (2019) Amer M. Zeidan et al. LEUKEMIA & LYMPHOMA
- Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysis
- (2019) Amer M. Zeidan et al. CANCER
- Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
- (2019) Amer M. Zeidan et al. LEUKEMIA & LYMPHOMA
- The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia
- (2019) Rory M. Shallis et al. BLOOD REVIEWS
- Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study
- (2019) Amy J. Davidoff et al. LEUKEMIA & LYMPHOMA
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience
- (2018) Pankit Vachhani et al. LEUKEMIA RESEARCH
- Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis
- (2017) Pin-Fang He et al. Oncotarget
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Comparative clinical effectiveness of azacitidineversusdecitabine in older patients with myelodysplastic syndromes
- (2016) Amer M. Zeidan et al. BRITISH JOURNAL OF HAEMATOLOGY
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from apost hocanalysis of a randomized phase III study
- (2014) Jianming He et al. LEUKEMIA & LYMPHOMA
- Lenalidomide performance in the real world
- (2013) Amer M. Zeidan et al. CANCER
- Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines
- (2013) Amy J. Davidoff et al. LEUKEMIA RESEARCH
- A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes
- (2013) Amy J. Davidoff et al. Journal of Geriatric Oncology
- Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
- (2012) A. Quintas-Cardama et al. BLOOD
- Survival for older patients with acute myeloid leukemia: a population-based study
- (2012) B. Oran et al. HAEMATOLOGICA
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study
- (2011) Haifa K. Al-Ali et al. LEUKEMIA & LYMPHOMA
- Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
- (2009) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
- (2009) Amanda F. Cashen et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search